Skip to main content

Drug Interactions between enzalutamide and momelotinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

enzalutamide momelotinib

Applies to: enzalutamide and momelotinib

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with potent CYP450 3A4 inducers may decrease the plasma concentration and therapeutic effects of momelotinib. The proposed mechanism is increased metabolism of momelotinib via the CYP450 3A4 isoenzyme. However, momelotinib is metabolized by multiple pathways and so the clinical significance is unclear. In a phase I study, coadministration of multiple doses of rifampin (600 mg once daily) following a single dose of momelotinib (200 mg) reduced the Cmax and AUC of momelotinib by 29% and 46%, respectively, when compared with a single dose of momelotinib (200 mg) plus a single dose of rifampin (600 mg). No data are available for use with other, less potent inducers.

MANAGEMENT: Caution and monitoring for decreased momelotinib efficacy may be required when used concomitantly with potent CYP450 3A4 inducers. An alternative agent with less potential for induction should be considered if possible.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer